image
Healthcare - Medical - Devices - NASDAQ - US
$ 12.3
0.572 %
$ 400 M
Market Cap
-13.23
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one NPCE stock under the worst case scenario is HIDDEN Compared to the current market price of 12.3 USD, NeuroPace, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one NPCE stock under the base case scenario is HIDDEN Compared to the current market price of 12.3 USD, NeuroPace, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one NPCE stock under the best case scenario is HIDDEN Compared to the current market price of 12.3 USD, NeuroPace, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart NPCE

image
$15.0$15.0$14.0$14.0$13.0$13.0$12.0$12.0$11.0$11.0$10.0$10.0$9.0$9.0$8.0$8.0$7.0$7.0$6.0$6.0$5.0$5.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
79.9 M REVENUE
22.14%
-21.7 M OPERATING INCOME
20.25%
-27.1 M NET INCOME
17.64%
-17.9 M OPERATING CASH FLOW
8.89%
8.99 M INVESTING CASH FLOW
-60.94%
4.33 M FINANCING CASH FLOW
-46.76%
21.5 M REVENUE
1.93%
-3.65 M OPERATING INCOME
13.91%
-5.25 M NET INCOME
3.71%
-4.8 M OPERATING CASH FLOW
-178.25%
1.96 M INVESTING CASH FLOW
40.07%
848 K FINANCING CASH FLOW
-70.74%
Balance Sheet NeuroPace, Inc.
image
Current Assets 81.3 M
Cash & Short-Term Investments 52.8 M
Receivables 12.9 M
Other Current Assets 15.7 M
Non-Current Assets 13.3 M
Long-Term Investments 0
PP&E 12.9 M
Other Non-Current Assets 413 K
55.74 %13.58 %16.62 %13.62 %Total Assets$94.6m
Current Liabilities 15.2 M
Accounts Payable 2.95 M
Short-Term Debt 1.86 M
Other Current Liabilities 10.3 M
Non-Current Liabilities 71.5 M
Long-Term Debt 71.5 M
Other Non-Current Liabilities 0
3.41 %11.94 %82.51 %Total Liabilities$86.6m
EFFICIENCY
Earnings Waterfall NeuroPace, Inc.
image
Revenue 79.9 M
Cost Of Revenue 20.8 M
Gross Profit 59.1 M
Operating Expenses 80.8 M
Operating Income -21.7 M
Other Expenses 5.47 M
Net Income -27.1 M
80m80m60m60m40m40m20m20m00(20m)(20m)(40m)(40m)80m(21m)59m(81m)(22m)(5m)(27m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
73.94% GROSS MARGIN
73.94%
-27.12% OPERATING MARGIN
-27.12%
-33.97% NET MARGIN
-33.97%
-338.71% ROE
-338.71%
-28.68% ROA
-28.68%
-26.64% ROIC
-26.64%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis NeuroPace, Inc.
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)(40m)(40m)202020202021202120222022202320232024202420252025
Net Income -27.1 M
Depreciation & Amortization 1.77 M
Capital Expenditures 0
Stock-Based Compensation 10.3 M
Change in Working Capital -5.45 M
Others -3.24 M
Free Cash Flow -17.9 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets NeuroPace, Inc.
image
Wall Street analysts predict an average 1-year price target for NPCE of $15.2 , with forecasts ranging from a low of $5.5 to a high of $20 .
NPCE Lowest Price Target Wall Street Target
5.5 USD -55.28%
NPCE Average Price Target Wall Street Target
15.2 USD 23.69%
NPCE Highest Price Target Wall Street Target
20 USD 62.60%
Price
Max Price Target
Min Price Target
Average Price Target
202018181616141412121010886644May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 13
6. Ownership
Insider Ownership NeuroPace, Inc.
image
Sold
0-3 MONTHS
50.7 M USD 2
3-6 MONTHS
1.3 M USD 1
6-9 MONTHS
578 K USD 1
9-12 MONTHS
1.59 M USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual Meeting MOUNTAIN VIEW, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, will be attending and presenting at the upcoming American Academy of Neurology (AAN) 2025 Annual Meeting, which is being held in San Diego from April 5 – 9. globenewswire.com - 2 weeks ago
NeuroPace Announces Refocusing of Product Portfolio -- Beginning of Wind Down of Stereo EEG (SEEG) Distribution Relationship in Q4 2025 -- -- Maintaining 2025 Revenue Guidance -- -- No Change to Long-Range Plan Expectations of Cash Flow Breakeven by the end of 2027 and Achievement of 20%+ Revenue CAGR -- MOUNTAIN VIEW, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported that as part of a strategic refocusing of its product portfolio on its core, differentiated RNS System product line, it is terminating its distribution relationship for SEEG products and will begin winding down the relationship in the fourth quarter of 2025 and continuing through the first quarter of 2026. globenewswire.com - 2 weeks ago
NeuroPace to Present at the 24th Annual Needham Virtual Healthcare Conference MOUNTAIN VIEW, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 24th Annual Needham Virtual Healthcare Conference at 3:00pm ET (12:00pm PT) on Tuesday, April 8, 2025. globenewswire.com - 3 weeks ago
NeuroPace, Inc. (NPCE) Q4 2024 Earnings Call Transcript NeuroPace, Inc. (NASDAQ:NPCE ) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET Company Participants Jeremy Feffer - Investor Relations Joel Becker - Chief Executive Officer and Board Member Rebecca Kuhn - Chief Financial Officer, Vice President, Finance and Administration Conference Call Participants Priya Sachdeva - UBS Rohin Patel - JP Morgan Frank Takkinen - Lake Street Capital Markets Mike Kratky - Leerink Partners Vik Chopra - Wells Fargo Matthew Park - Cantor Fitzgerald Michael Pollard - Wolfe Research Operator Greetings and welcome to NeuroPace Fourth Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode. seekingalpha.com - 1 month ago
NeuroPace Reports Fourth Quarter and Full Year 2024 Financial Results -- Record quarterly revenue of $21.5 million in Q4 2024 -- -- Full-year 2025 revenue guidance of $92 to $96 million -- globenewswire.com - 1 month ago
UPDATE – NeuroPace to Present at the Leerink Partners Global Healthcare Conference MOUNTAIN VIEW, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the Leerink Partners 2025 Global Healthcare Conference at 4:20pm ET (1:20pm PT) on Monday, March 10, 2025, in Miami, FL. Management will also host investor meetings during the conference. globenewswire.com - 1 month ago
NeuroPace to Present at the Leerink Partners Global Healthcare Conference MOUNTAIN VIEW, Calif. , March 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the Leerink Partners 2025 Global Healthcare Conference at 4:20pm ET (1:20pm PT) on Monday, January 10, 2025, in Miami, FL. Management will also host investor meetings during the conference. globenewswire.com - 1 month ago
NeuroPace (NPCE) Surges 5.8%: Is This an Indication of Further Gains? NeuroPace (NPCE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. zacks.com - 1 month ago
NeuroPace Completes Repurchase of 5.3 Million Shares of Its Common Stock from KCK Ltd. MOUNTAIN VIEW, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it has completed the previously announced plan to repurchase 5,270,845 shares of the Company's common stock from KCK Ltd. The repurchase of these shares allowed for the organized sale by KCK Ltd. of all remaining shares it held in the Company. NeuroPace funded the repurchase of these shares using a portion of the proceeds from its recent underwritten public offering. NeuroPace also strengthened its balance sheet following the closing of the public offering, which the Company now anticipates will be sufficient to support its planned operations until achieving cash flow breakeven. Additionally, the Company terminated its current at-the-market (ATM) offering program. globenewswire.com - 1 month ago
NeuroPace to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025 MOUNTAIN VIEW, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the fourth quarter and full year of 2024 after market close on Tuesday, March 4, 2025. globenewswire.com - 1 month ago
NeuroPace Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares MOUNTAIN VIEW, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE) today announced the completion of its previously announced underwritten public offering of 7,475,000 shares of its common stock at a public offering price of $10.00 per share, including 975,000 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares. globenewswire.com - 2 months ago
NeuroPace Announces Pricing of Public Offering of $65 Million of Common Stock MOUNTAIN VIEW, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE) today announced the pricing of an underwritten public offering of 6,500,000 shares of its common stock at a public offering price of $10.00 per share. globenewswire.com - 2 months ago
8. Profile Summary

NeuroPace, Inc. NPCE

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 400 M
Dividend Yield 0.00%
Description NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
Contact 455 North Bernardo Avenue, Mountain View, CA, 94043 https://www.neuropace.com
IPO Date April 22, 2021
Employees 184
Officers Ms. Katie Keller Vice President of Marketing Ms. Amy Treadwell Vice President of Human Resources Mr. Joel D. Becker Chief Executive Officer, President & Director Dr. Martha J. Morrell M.D. Chief Medical Officer Ms. Kelley Nicholas Vice President of Sales Mr. Dylan St. John Chief of Operations & Development Ms. Leah Akin General Counsel & Corporate Secretary Ms. Rebecca L. Kuhn Chief Financial Officer and Vice President of Finance & Administration